TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Recommendation of “Buy” by Brokerages

Shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) have been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $10.75.

A number of equities analysts have recently commented on TLSI shares. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a report on Thursday, February 13th. They issued a “buy” rating and a $10.00 target price on the stock.

Insider Activity at TriSalus Life Sciences

In other news, insider Richard Marshak sold 6,597 shares of TriSalus Life Sciences stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $5.18, for a total transaction of $34,172.46. Following the sale, the insider now owns 69,101 shares in the company, valued at $357,943.18. This trade represents a 8.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 16,125 shares of company stock worth $83,528. Company insiders own 27.50% of the company’s stock.

Institutional Trading of TriSalus Life Sciences

Hedge funds have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. purchased a new stake in shares of TriSalus Life Sciences during the first quarter valued at approximately $55,000. Renaissance Technologies LLC purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $67,000. Connective Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at approximately $140,000. Northern Trust Corp grew its position in shares of TriSalus Life Sciences by 22.7% during the fourth quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock worth $161,000 after buying an additional 5,936 shares in the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of TriSalus Life Sciences during the first quarter worth approximately $187,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Trading Up 0.9%

TriSalus Life Sciences stock opened at $5.39 on Friday. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $6.62. The stock has a market cap of $203.95 million, a P/E ratio of -2.16 and a beta of 0.47. The company has a 50-day moving average price of $5.39 and a 200 day moving average price of $5.13.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The firm had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period last year, the firm posted ($0.60) earnings per share. As a group, analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current year.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.